A high dose of the investigational gene therapy AAV-GAD, which delivers the glutamic acid decarboxylase ( GAD) gene to the ...

The incubator is designed to draw cell and gene therapy researchers and drugmakers to work at the hub, where they can develop ...

A Phase I/II trial (NCT05603312) with MeiraGTx's AAV-GAD Parkinson’s disease gene therapy has met its primary endpoint. The sham-controlled bridging study evaluated the company's AAV-GAD therapy ...

Armed with data from a small phase 1/2 bridging study, MeiraGTx is preparing to take its gene therapy for Parkinson's disease into a pivotal trial. Shares in the Anglo-US biotech rose sharply ...

The AAV-GAD bridging study met the primary endpoint of safety and tolerability, and showed early promise in Parkinson’s ...

Two oral presentations and nine poster presentations will highlight exciting progress in AskBio’s clinical and pre-clinical ...

Advancements in organoid technology are crucial for Parkinson's disease research, providing human-relevant models for ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator ...

allowing certain patients with anti-AAV antibodies to still be candidates for CNS-directed gene therapy. "In particular, an AAV2-GAD therapy in Parkinson's disease patients demonstrated that ...

The Michael J. Fox Foundation (MJFF) has launched a major new initiative to rapidly expedite development of therapeutic ...